




ZOOM on Scientific Breakthrough in breast cancer

- FOCUS: Complementary pre-clinical offering on microbiota powered by Oncodesign. At the forefront of precision medicine using microbiota signature
- FOCUS: End-to-end microbiota offering powered by Biofortis
- FOCUS: Design and implementation of precision medicine clinical trials including gut microbiota
- WEB-CATALOGUE: 25 new PDX models to ease & optimize *in vivo/ in vitro* translational research



ZOOM

Scientific breakthrough in breast cancer



IMODI (Innovative MODEls Initiative) is a French consortium, involving both academic and private partners. The goal of the consortium is to develop new experimental models for the diagnosis and treatment in cancer. The IMODI project includes 4 observational clinical studies in breast, ovary, prostate, and liver cancers. As part of the scientific valorization of IMODI, we recently focused our efforts on the breast cancer study, conducted by 2 referral cancer centers (Centre Léon-Bérard in Lyon and Centre Georges François Leclerc in Dijon). This led to the submission of 4 conference abstracts since January 2019.

 [Read the article](#)

FOCUS




Complementary pre-clinical offering on microbiota powered by oncodesign at the forefront of precision medicine using microbiota signature

It is now known that the human microbiota, which consists of a wide variety of microorganisms, plays a much larger role in human health & disease than previously assumed.

Oncodesign developed models for pathologies related to microbiota disorders and so can customize studies for **programs from preclinical to early clinical phases**.

 [Read detailed article](#)

FOCUS



Design and implementation of precision medicine clinical trials including gut microbiota :

Identification of gut microbiota as surrogate end-points and clinical biomarkers of response to treatment

Using its Artificial Intelligence platform KEM®, Ariana integrates gut microbiota data with clinical and omic parameters enabling extensive patient stratification strategies.

Use of Artificial Intelligence allows applying this technology as early as the preclinical steps (animal models) and early development phases (I and II) with limited number of patients.

 [Read detailed article](#)

FOCUS



End-to-end microbiota offering powered by Biofortis

Biofortis is Mérieux Nutrisciences' CRO serving health and innovation to offer complementary, differentiating and innovative services including pre-clinical and clinical assessments as well as microbiota-related analyses and their scientific interpretation. Our aim is to enable clients to substantiate their products in order to maximize their market impact.

These services may for example be :

- The assessment of real and measured efficacy with high quality services in clinical trials including metabolic and physiological exploration
- Microbiota research studies to determine the impact of pharmaceuticals and other products on the microbiota (intestinal, cutaneous, oral ...)

[Read detailed article](#)

WEB-CATALOGUE



Webcatalogue

25 new PDX models to ease & optimize *in vivo* / *in vitro* translational research
It is over **160 PDX** models available to assess efficacy of your drug in **5 main therapeutic areas**: Breast, Ovary, Pancreas, Lung & Liver.

[Visit our webcatalogue](#)

Human cancer in vitro models for preclinical oncology drug development

About 40 defined in vitro cells models (Breast, Ovary, Prostate, Lungs, Liver, Lymphoma, Pancreas) from both highly characterized primary tumor cells and from PDX are available in the IMODI webcatalogue.

CTIBiotech also develop 3D-bioprinted microtumours reproducing the interactions between human cancer cells and the tumor microenvironment.

[Read the article](#)



Model and treat the diversity of cancers

2013/01/01: Creation of the consortium

2013/09/01: Signature of the consortium agreement

2015/10/01: Signature of the 1st licence agreement

7 years: duration of the 1st R&D phase

150 Researchers

6 SMEs

4 pharmaceutical industries

8 Academic institutions

IMODI at a glance



The French IMODI (Innovative MODEls Initiative) consortium is dedicated to the development, the characterization and the commercialization of new preclinical models in oncology.

IMODI is a public-private consortium of 18 partners pooling their resources for the development of more valuable models of cancer in order to decrease the attrition rate of clinical development of novel anti-cancer agents.

Science and technology developments:



Developing PDX models and cellular assays



Modelling the human tumour microenvironment in mice



Studying the relationship between microbiota and cancer

IMODI's partners

